Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease

Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjögren's syndrome

(2014) L. A. Aqrawi et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The E3 Ubiquitin Ligase Ro52 Negatively Regulates IFN-  Production Post-Pathogen Recognition by Polyubiquitin-Mediated Degradation of IRF3

(2014) R. Higgs et al.   JOURNAL OF IMMUNOLOGY

Expression of the Immune Regulator Tripartite-Motif 21 Is Controlled by IFN Regulatory Factors

(2013) M. Sjostrand et al.   JOURNAL OF IMMUNOLOGY

Ro52/SSA sensitizes cells to death receptor-induced apoptosis by down-regulating c-FLIP(L)

(2012) Jing Zhang et al.   CELL BIOLOGY INTERNATIONAL

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

(2012) C Visco et al.   LEUKEMIA

SS-A/Ro52 promotes apoptosis by regulating Bcl-2 production

(2011) Siti Nur Aisyah Jauharoh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Expression of APRIL in Diffuse Large B Cell Lymphomas from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

(2011) B. LOFSTROM et al.   JOURNAL OF RHEUMATOLOGY

LMO2 protein expression predicts survival in patients with rheumatoid arthritis and diffuse large B-cell lymphoma

(2011) Eva Baecklund et al.   LEUKEMIA & LYMPHOMA

Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma

(2011) Catarina Dias et al.   Nature Reviews Rheumatology

Fas-associated Death Domain (FADD) and the E3 Ubiquitin-Protein Ligase TRIM21 Interact to Negatively Regulate Virus-induced Interferon Production

(2010) Jennifer A. Young et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes

(2010) Ali Bazarbachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Ro52-mediated Monoubiquitination of IKK  Down-regulates NF- B Signalling

(2009) K. Wada et al.   JOURNAL OF BIOCHEMISTRY

Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathway

(2009) Alexander Espinosa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Gene Disruption Study Reveals a Nonredundant Role for TRIM21/Ro52 in NF- B-Dependent Cytokine Expression in Fibroblasts

(2009) R. Yoshimi et al.   JOURNAL OF IMMUNOLOGY

High Ro52 Expression in Spontaneous and UV-Induced Cutaneous Inflammation

(2009) Vilija Oke et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

(2008) Kai Fu et al.   JOURNAL OF CLINICAL ONCOLOGY